PET Imaging of brain muscarinic receptors with 18F-Fluorobenzyl-Dexetimide: A first in human study.

2021-08-08

Rowe, Christopher C

Krishnadas, Natasha

Ackermann, Uwe

Doré, Vincent

Goh, Rachel Y W

Guzman, Rodney

Chong, Lee

Bozinovski, Svetlana

Mulligan, Rachel S

Kanaan, Richard A A

Dean, Brian

Villemagne, Victor L

Brain distribution

Fluorine-18

Muscarinic acetylcholine receptors

Neuroreceptor imaging

Positron emission tomography

Radiopharmaceutical

Schizophrenia

Journal Article

10.1016/j.pscychresns.2021.111354

M1 and M4 muscarinic receptor (mAChR) agonists are under development for the treatment of schizophrenia, Alzheimer's and Parkinson's disease. We performed first-in-human PET imaging of mAChR with 18F-Fluorobenzyl-Dexetimide (FDEX) in 10 healthy participants (29.4±4.3yrs). Four underwent dynamic brain scanning for 240 min, and then six underwent static brain scans at 120 and 160-min post injection of 250 MBq of FDEX. Gjedde-Patlak graphical analysis was applied to determine the influx constant (Ki). Regional tissue ratios (SUVR) were calculated using the cerebellar cortex as the reference region. No adverse events were observed. The tracer showed good brain entry (∼4.2% ID at 5 min) but irreversible distribution kinetics over four hours in regions of high mAChR. Binding was consistent with the distribution of mAChR receptors with striatum > cortex > hippocampus >> thalamus >>> cerebellum with low variance in regional binding between subjects. Ki was 0.42±0.04 in the putamen, 0.27±0.01 in frontal cortex, 0.25±0.02 in the hippocampus and 0.10±0.01 in the thalamus. SUVR at 120 and 240 min. were highly correlated with these Ki values with R2 of 0.91 and 0.99 respectively. FDEX yields high quality brain images with uptake in the known distribution of mAChR with remarkably little variance between normal subjects.

link

Psychiatry Research. Neuroimaging 2021; 316: 111354

Psychiatry Research. Neuroimaging